Royalty Pharma (NASDAQ:RPRX) Raised to “Strong-Buy” at TD Cowen

Royalty Pharma (NASDAQ:RPRX) was upgraded by equities researchers at TD Cowen to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

A number of other research firms also recently commented on RPRX. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Citigroup reduced their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $41.67.

Royalty Pharma Trading Down 0.1 %

NASDAQ:RPRX opened at $25.23 on Tuesday. The company has a market cap of $14.87 billion, a PE ratio of 13.07, a P/E/G ratio of 4.36 and a beta of 0.46. The business’s 50 day moving average is $26.26 and its two-hundred day moving average is $27.11. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $31.66.

Hedge Funds Weigh In On Royalty Pharma

Several institutional investors have recently modified their holdings of RPRX. Franklin Resources Inc. lifted its position in Royalty Pharma by 5.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after purchasing an additional 70,130 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Royalty Pharma during the third quarter valued at approximately $61,000. Sanctuary Advisors LLC boosted its position in shares of Royalty Pharma by 78.9% during the third quarter. Sanctuary Advisors LLC now owns 41,466 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 18,288 shares during the period. Hohimer Wealth Management LLC boosted its position in shares of Royalty Pharma by 1.0% during the third quarter. Hohimer Wealth Management LLC now owns 145,357 shares of the biopharmaceutical company’s stock worth $4,112,000 after buying an additional 1,445 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock worth $205,562,000 after buying an additional 417,490 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.